Table 2.

Characteristics and main findings of the six systematic reviews and meta-analysis included.

Author	Year	Number of Qualitatative Studies	Number of Patients	miR		Qualitative Studies		Quantitative Studies
					Level of Regulation	OS	DFS	OS HR (95% CI)	DFS HR (95% CI)
Fu X	2011	4	422	21	U	− *		1.46 (1.13–1.87)
Jamali Z	2015	25	2006	17, 20a, 153, 200c, 203, 375, 451, Let-7g	D	− *
				193b, 205	D		− *
				126a	D		−
				18a, 19a, 20a, 21	U	− *
				134a, 201	U		− *
				155	U	−		1.57 (1.22–2.02)	1.00 (0.42–2.6)
Lubov J	2017	116	8194	17, 20c, 21a, 26a, 195, 203, 218, 375, Lin28B	D	− *
				34a, 34c-5p, 126a, Let7d, Let-7g	D		− *
				205, 451	D	− *	− *
				9, 18a, 19a, 20a, 23a, 155, 206, 210, 1246	U	− *
				21	U	− *		1.81 (0.66–2.95)
				130b-3p, 134, 196a, 213p, 372, 373, 965p, 1413p	U		− *
Troiano G	2018	15	1200	16	D		−	1.95 (1.28–2.98)
				17	D	− *		2.65 (2.07–3.3
				20a, 32, 204	D	−
				101, 125	D	− *
				21, 155-5p, 196a, 372, 373, 455-5p	U	−
				29b, 181a, 181b, 1246	U	− *
Kumarasamy C	2019	50	6867	34a	D				0.19 (0.01–130.51)
				34c-5p	D			4.36 (2.38–8.00)
				200b	D			1.19 (0.66–2.18)
				let-7g, 17, 20a, 26a, 29c, 34c-5p, 142, 146a, 155, 195, 200b, 203, 212, 218, 300, 375, 451, 548b	D			2.02 (1.42–2.86)
				18a	U			1.87 (1.05–3.33)
				21	U			1.59 (1.15–2.19)	1.47 (0.81–0.27)
				125b	U			2.3 (0.40–13.40)
				let7a, 9, 18a, 19a, 20a, 21, 93, 100, 125b, 155, 206, 375, 377-3p, 483-5p, 1246	U			1.76 (1.43–2.17)
				34, 126a, 205	D				2.10 (0.72–6.17)
				21, 21-3p, 96-5p, 130b-3p, 134, 141-3p, 210, 372, 373	U				2.64 (1.92–3.66)
				34, 126a, 205; 21, 21-3p, 96-5p, 130b-3p, 134, 141-3p, 210, 372, 373	D and U				2.60 (1.91–3.51)
Sabarimurugan S	2019	21	5069	92b	D	+
				18b, 184, 324-3p, 3188	D	+ *
				29c, 103, 204, 451, 483-5p,744	D	− *
				18b, 29c, 92b, 103, 184, 204, 324-3p, 451, 483-5p, 744, 3188,	D			0.95 (0.65–1.39)
				663, let-7c	U	−
				19b-3p, 18a, 29a, 92a	U	+ *
				10b,17-5p, 21, 22, 572, 638, 1234	U	− *
				18b, 29c, 92b, 103, 184, 204, 324-3p, 451, 483-5p, 744, 3188	D			0.95 (0.65–1.39)
				let-7c, 10b, 17-5p, 18a, 19b-3p, 21, 22, 29a, 92a, 572, 638, 663, 1234,	U			1.64 (1.05–2.58)
				18b, 29c, 92b, 103, 184, 204, 324-3p, 451, 483-5p, 744, 3188; let-7c, 10b, 17-5p, 18a, 19b-3p, 21, 22, 29a, 92a, 572, 638, 663, 1234,	D and U			1.19 (0.89–1.60)

U—miR is upregulated; D—miR is downregulated; − or + represent reduced or increased, respectively; OS or DFS according to the column; * = statistically significant; in bold, different miRs HRs (95% CI) were pooled together in a meta-analysis, performed to obtain an overall estimate of their effect when combined. Non-bold miRs are those that, in separate analysis by type of miR, showed the same level of regulation, association and significance in the OS or DFS.